RU2014121335A - Иммуногенное лечение рака - Google Patents

Иммуногенное лечение рака Download PDF

Info

Publication number
RU2014121335A
RU2014121335A RU2014121335A RU2014121335A RU2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A RU 2014121335 A RU2014121335 A RU 2014121335A
Authority
RU
Russia
Prior art keywords
immunomodulator
cancer
therapy
paragraphs
tumor
Prior art date
Application number
RU2014121335A
Other languages
English (en)
Russian (ru)
Inventor
Чарльз ЭКЛ
Сатвиндер МУДАН
Джон ГРАНДЖ
Original Assignee
Иммодулон Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммодулон Терапьютикс Лимитед filed Critical Иммодулон Терапьютикс Лимитед
Publication of RU2014121335A publication Critical patent/RU2014121335A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014121335A 2011-12-02 2012-12-03 Иммуногенное лечение рака RU2014121335A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1120779.2 2011-12-02
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (1)

Publication Number Publication Date
RU2014121335A true RU2014121335A (ru) 2016-01-27

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014121335A RU2014121335A (ru) 2011-12-02 2012-12-03 Иммуногенное лечение рака

Country Status (15)

Country Link
US (4) US20140356397A1 (enExample)
EP (1) EP2785361B1 (enExample)
JP (1) JP6085611B2 (enExample)
KR (1) KR20140097419A (enExample)
CN (1) CN104023733A (enExample)
AU (1) AU2012343536B2 (enExample)
BR (1) BR112014012880A2 (enExample)
CA (1) CA2857429A1 (enExample)
GB (1) GB201120779D0 (enExample)
IL (1) IL232890A0 (enExample)
IN (1) IN2014MN00955A (enExample)
MX (1) MX2014006511A (enExample)
RU (1) RU2014121335A (enExample)
SG (1) SG11201402396XA (enExample)
WO (1) WO2013079980A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2015102680A2 (en) 2013-09-11 2015-07-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for beam intensity-modulation to facilitate rapid radiation therapies
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
WO2016207646A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
EP3600551A1 (en) 2017-03-28 2020-02-05 Emblation Limited Stenosis treatment
US11173325B2 (en) * 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
KR20210099073A (ko) 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
TW202138005A (zh) * 2019-12-27 2021-10-16 特定非營利活動法人北東日本研究機構 癌症治療方法及醫藥
WO2022101619A1 (en) 2020-11-10 2022-05-19 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
WO2023007107A1 (en) * 2021-07-27 2023-02-02 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008488A1 (en) * 1990-11-08 1992-05-29 University College London Mycobacterium as adjuvant for antigens
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
AU2006306521B2 (en) 2005-10-21 2011-12-22 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by TLR ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
US9114158B2 (en) * 2011-03-09 2015-08-25 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
WO2020002905A1 (en) 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы

Also Published As

Publication number Publication date
EP2785361A1 (en) 2014-10-08
CN104023733A (zh) 2014-09-03
US20230149525A1 (en) 2023-05-18
AU2012343536A1 (en) 2014-06-05
KR20140097419A (ko) 2014-08-06
MX2014006511A (es) 2014-12-05
US11318193B2 (en) 2022-05-03
BR112014012880A2 (pt) 2017-06-13
EP2785361B1 (en) 2018-11-28
AU2012343536B2 (en) 2017-08-24
NZ624994A (en) 2016-10-28
US20140356397A1 (en) 2014-12-04
JP6085611B2 (ja) 2017-02-22
IL232890A0 (en) 2014-07-31
CA2857429A1 (en) 2013-06-06
JP2014533743A (ja) 2014-12-15
US20190224294A1 (en) 2019-07-25
US11554166B2 (en) 2023-01-17
GB201120779D0 (en) 2012-01-11
SG11201402396XA (en) 2014-10-30
IN2014MN00955A (enExample) 2015-04-24
US20200338181A1 (en) 2020-10-29
WO2013079980A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
JP6085611B2 (ja) 癌免疫療法
JP2014533743A5 (enExample)
Moskalik et al. The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd: YAG lasers
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
EA200501937A1 (ru) Способ лечения злокачественных опухолей
McCaughan Jr et al. Hematoporphyrin‐derivative and photoradiation therapy of malignant tumors
RU2015143106A (ru) Терапия злокачественных опухолей
PH12015502260B1 (en) C. novyi for the treatment of solid tumors in humans
CA2929284C (en) Apparatus for damaging cancerous cells utilizing radio frequency waves in heating with heating enhanced by infusion or injection of glucose
PT1276501E (pt) Metodo para o tratamento de tumores utilizando terapia fotodinamica
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
Ohyama et al. Laserthermia on head and neck malignancies—experimental and clinical studies
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
RU2466759C1 (ru) Способ лечения больных первичной меланомой кожи
Stranadko et al. 24 PHOTODYNAMIC THERAPY FOR SKIN CANCER WITH CHLORIN DERIVATIVES UNDER THE OUTPATIENT CONDITIONS
JP2017202274A (ja) 遠赤外線がん温熱治療器
RU2004123049A (ru) Способ лучевого лечения больных злокачественными лимфомами
JP6978053B2 (ja) 遠赤外線がん温熱治療器ii
RU2617090C1 (ru) Способ фотодинамической терапии злокачественных опухолей
Kaplan et al. 23 PHOTODYNAMIC THERAPY IN COMBINED TREATMENT MODALITIES OF DISSEMINATED MELANOMA
CA2829719C (en) Focal photodynamic therapy methods
RU2286814C1 (ru) Способ лечения рака кожи и слизистых оболочек
RU2289455C1 (ru) Способ лечения метастазов
Gardner et al. Quantitative analysis of effect of neodymium-YAG laser on transplanted mouse carcinomas.
Kapinus et al. 22 PHOTODYNAMIC THERAPY OF LOCALLY INVASIVE CUTANEOUS CARCINOMA